other material
confidence high
sentiment positive
materiality 0.85
Immunovant reports 76% response rate in Graves' Disease Phase 2a; IND cleared for IMVT-1402 pivotal trial
Immunovant, Inc.
- High-dose batoclimab (680 mg SC weekly) achieved 76% response rate and 56% ATD-free response at week 12 in patients uncontrolled on antithyroid drugs.
- Lower-dose batoclimab (340 mg) yielded 68% response and 36% ATD-free response; 70%+ IgG reduction linked to nearly 3x higher ATD-free response.
- FDA IND cleared; pivotal trial of IMVT-1402 in Graves' Disease expected to initiate by December 31, 2024.
- Real-world claims data indicate 25–30% of GD patients per year are uncontrolled on ATDs with limited existing therapeutic options.